Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
As the number of therapeutic options expand for patients with psoriatic arthritis (PsA), rheumatology providers are challenged with absorbing an escalating volume of clinical trial data. Moreover, the complexity and heterogeneity of PsA require clinicians to personalize treatment options based on a solid comprehension of the different mechanism of actions of these targeted therapies. Recently, the addition of head to head trials in PsA have provided novel insights that are informative to the practitioner. Studies on patient-reported outcomes provide essential information that impact patient response and satisfaction but more work is needed to integrate PROs into routine decision making for our PsA patients. More rheumatology clinicians are involved in co-management with dermatology than ever before. At this session, faculty will review clinical trial translations of novel targeted therapies, share patient-reported outcomes data, and update co-management strategies between rheumatologists and dermatologists. In particular, the session will address the challenges of managing psoriatic arthritis in an individual patient and provide expert insights regarding therapeutic strategies for the individual, or "patients like me."